Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients

Effects on the neonatal abstinence syndrome

Hendree E. Jones, Rolley E. Johnson, Donald R. Jasinski, Kevin E. O'Grady, Christian A. Chisholm, Robin E. Choo, Michael Crocetti, Robert A Dudas, Cheryl Harrow, Marilyn A. Huestis, Lauren M Jansson, Michael Lantz, Barry M. Lester, Lorraine A Milio

Research output: Contribution to journalArticle

Abstract

This study was designed to compare the neonatal abstinence syndrome (NAS) in neonates of methadone and buprenorphine maintained pregnant opioid-dependent women and to provide preliminary safety and efficacy data for a larger multi-center trial. This randomized, double-blind, double-dummy, flexible dosing, parallel-group controlled trial was conducted in a comprehensive drug-treatment facility that included residential and ambulatory care. Participants were opioid-dependent pregnant women and their neonates. Treatment involved daily administration of either sublingual buprenorphine or oral methadone using flexible dosing of 4-24 mg or 20-100 mg, respectively. Primary a priori outcome measures were: (1) number of neonates treated for NAS; (2) amount of opioid agonist medication used to treat NAS; (3) length of neonatal hospitalization; and (4) peak NAS score. Two of 10 (20%) buprenorphine-exposed and 5 of 11 (45.5%) methadone-exposed neonates were treated for NAS (p = .23). Total amount of opioid-agonist medication administered to treat NAS in methadone-exposed neonates was three times greater than for buprenorphine- exposed neonates (93.1 versus 23.6; p = .13). Length of hospitalization was shorter for buprenorphine-exposed than for methadone-exposed neonates (p = .021). Peak NAS total scores did not significantly differ between groups (p = .25). Results suggest that buprenorphine is not inferior to methadone on outcome measures assessing NAS and maternal and neonatal safety when administered starting in the second trimester of pregnancy.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalDrug and Alcohol Dependence
Volume79
Issue number1
DOIs
StatePublished - Jul 1 2005

Fingerprint

Neonatal Abstinence Syndrome
Buprenorphine
Methadone
hospitalization
Opioid Analgesics
medication
Newborn Infant
pregnancy
Group
drug
Therapeutics
Drug therapy
Hospitalization
Sublingual Administration
Outcome Assessment (Health Care)
Residential Facilities
Safety
Second Pregnancy Trimester
Ambulatory Care
Pregnant Women

Keywords

  • Buprenorphine
  • Infants
  • Methadone
  • NAS
  • Opioids
  • Prenatal
  • Women

ASJC Scopus subject areas

  • Medicine(all)
  • Behavioral Neuroscience
  • Toxicology
  • Health(social science)

Cite this

Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients : Effects on the neonatal abstinence syndrome. / Jones, Hendree E.; Johnson, Rolley E.; Jasinski, Donald R.; O'Grady, Kevin E.; Chisholm, Christian A.; Choo, Robin E.; Crocetti, Michael; Dudas, Robert A; Harrow, Cheryl; Huestis, Marilyn A.; Jansson, Lauren M; Lantz, Michael; Lester, Barry M.; Milio, Lorraine A.

In: Drug and Alcohol Dependence, Vol. 79, No. 1, 01.07.2005, p. 1-10.

Research output: Contribution to journalArticle

Jones, Hendree E. ; Johnson, Rolley E. ; Jasinski, Donald R. ; O'Grady, Kevin E. ; Chisholm, Christian A. ; Choo, Robin E. ; Crocetti, Michael ; Dudas, Robert A ; Harrow, Cheryl ; Huestis, Marilyn A. ; Jansson, Lauren M ; Lantz, Michael ; Lester, Barry M. ; Milio, Lorraine A. / Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients : Effects on the neonatal abstinence syndrome. In: Drug and Alcohol Dependence. 2005 ; Vol. 79, No. 1. pp. 1-10.
@article{169ecba9fd474c2399db835156e58e2c,
title = "Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: Effects on the neonatal abstinence syndrome",
abstract = "This study was designed to compare the neonatal abstinence syndrome (NAS) in neonates of methadone and buprenorphine maintained pregnant opioid-dependent women and to provide preliminary safety and efficacy data for a larger multi-center trial. This randomized, double-blind, double-dummy, flexible dosing, parallel-group controlled trial was conducted in a comprehensive drug-treatment facility that included residential and ambulatory care. Participants were opioid-dependent pregnant women and their neonates. Treatment involved daily administration of either sublingual buprenorphine or oral methadone using flexible dosing of 4-24 mg or 20-100 mg, respectively. Primary a priori outcome measures were: (1) number of neonates treated for NAS; (2) amount of opioid agonist medication used to treat NAS; (3) length of neonatal hospitalization; and (4) peak NAS score. Two of 10 (20{\%}) buprenorphine-exposed and 5 of 11 (45.5{\%}) methadone-exposed neonates were treated for NAS (p = .23). Total amount of opioid-agonist medication administered to treat NAS in methadone-exposed neonates was three times greater than for buprenorphine- exposed neonates (93.1 versus 23.6; p = .13). Length of hospitalization was shorter for buprenorphine-exposed than for methadone-exposed neonates (p = .021). Peak NAS total scores did not significantly differ between groups (p = .25). Results suggest that buprenorphine is not inferior to methadone on outcome measures assessing NAS and maternal and neonatal safety when administered starting in the second trimester of pregnancy.",
keywords = "Buprenorphine, Infants, Methadone, NAS, Opioids, Prenatal, Women",
author = "Jones, {Hendree E.} and Johnson, {Rolley E.} and Jasinski, {Donald R.} and O'Grady, {Kevin E.} and Chisholm, {Christian A.} and Choo, {Robin E.} and Michael Crocetti and Dudas, {Robert A} and Cheryl Harrow and Huestis, {Marilyn A.} and Jansson, {Lauren M} and Michael Lantz and Lester, {Barry M.} and Milio, {Lorraine A}",
year = "2005",
month = "7",
day = "1",
doi = "10.1016/j.drugalcdep.2004.11.013",
language = "English (US)",
volume = "79",
pages = "1--10",
journal = "Drug and Alcohol Dependence",
issn = "0376-8716",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients

T2 - Effects on the neonatal abstinence syndrome

AU - Jones, Hendree E.

AU - Johnson, Rolley E.

AU - Jasinski, Donald R.

AU - O'Grady, Kevin E.

AU - Chisholm, Christian A.

AU - Choo, Robin E.

AU - Crocetti, Michael

AU - Dudas, Robert A

AU - Harrow, Cheryl

AU - Huestis, Marilyn A.

AU - Jansson, Lauren M

AU - Lantz, Michael

AU - Lester, Barry M.

AU - Milio, Lorraine A

PY - 2005/7/1

Y1 - 2005/7/1

N2 - This study was designed to compare the neonatal abstinence syndrome (NAS) in neonates of methadone and buprenorphine maintained pregnant opioid-dependent women and to provide preliminary safety and efficacy data for a larger multi-center trial. This randomized, double-blind, double-dummy, flexible dosing, parallel-group controlled trial was conducted in a comprehensive drug-treatment facility that included residential and ambulatory care. Participants were opioid-dependent pregnant women and their neonates. Treatment involved daily administration of either sublingual buprenorphine or oral methadone using flexible dosing of 4-24 mg or 20-100 mg, respectively. Primary a priori outcome measures were: (1) number of neonates treated for NAS; (2) amount of opioid agonist medication used to treat NAS; (3) length of neonatal hospitalization; and (4) peak NAS score. Two of 10 (20%) buprenorphine-exposed and 5 of 11 (45.5%) methadone-exposed neonates were treated for NAS (p = .23). Total amount of opioid-agonist medication administered to treat NAS in methadone-exposed neonates was three times greater than for buprenorphine- exposed neonates (93.1 versus 23.6; p = .13). Length of hospitalization was shorter for buprenorphine-exposed than for methadone-exposed neonates (p = .021). Peak NAS total scores did not significantly differ between groups (p = .25). Results suggest that buprenorphine is not inferior to methadone on outcome measures assessing NAS and maternal and neonatal safety when administered starting in the second trimester of pregnancy.

AB - This study was designed to compare the neonatal abstinence syndrome (NAS) in neonates of methadone and buprenorphine maintained pregnant opioid-dependent women and to provide preliminary safety and efficacy data for a larger multi-center trial. This randomized, double-blind, double-dummy, flexible dosing, parallel-group controlled trial was conducted in a comprehensive drug-treatment facility that included residential and ambulatory care. Participants were opioid-dependent pregnant women and their neonates. Treatment involved daily administration of either sublingual buprenorphine or oral methadone using flexible dosing of 4-24 mg or 20-100 mg, respectively. Primary a priori outcome measures were: (1) number of neonates treated for NAS; (2) amount of opioid agonist medication used to treat NAS; (3) length of neonatal hospitalization; and (4) peak NAS score. Two of 10 (20%) buprenorphine-exposed and 5 of 11 (45.5%) methadone-exposed neonates were treated for NAS (p = .23). Total amount of opioid-agonist medication administered to treat NAS in methadone-exposed neonates was three times greater than for buprenorphine- exposed neonates (93.1 versus 23.6; p = .13). Length of hospitalization was shorter for buprenorphine-exposed than for methadone-exposed neonates (p = .021). Peak NAS total scores did not significantly differ between groups (p = .25). Results suggest that buprenorphine is not inferior to methadone on outcome measures assessing NAS and maternal and neonatal safety when administered starting in the second trimester of pregnancy.

KW - Buprenorphine

KW - Infants

KW - Methadone

KW - NAS

KW - Opioids

KW - Prenatal

KW - Women

UR - http://www.scopus.com/inward/record.url?scp=27644438279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27644438279&partnerID=8YFLogxK

U2 - 10.1016/j.drugalcdep.2004.11.013

DO - 10.1016/j.drugalcdep.2004.11.013

M3 - Article

VL - 79

SP - 1

EP - 10

JO - Drug and Alcohol Dependence

JF - Drug and Alcohol Dependence

SN - 0376-8716

IS - 1

ER -